NG-641 Plus Nivolumab to be Assessed in Previously Treated Metastatic or Advanced Epithelial Tumors


The safety and efficacy of NG-641 plus nivolumab will be assessed as part of the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumor.

NG-641, a novel adenoviral vector, is under investigation in combination with nivolumab (Opdivo) as part of the phase 1a/b NEBULA trial (NCT05043714) in a population of patients with previously treated metastatic or advanced epithelial tumors

The open-label, dose-escalating trial is investigating the safety and preliminary efficacy of the adenoviral vector. Details of the ongoing trial were presented in a poster at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

NG-641 is a next-generation blood-stable and transgene-armed T-SIGn adenoviral vector. T-SIGn vectors allow for intravenous administration for selective infection of cancer cells as well as replication at tumor sites. Activated immune cells from the therapy support functional anti-tumor responses.

The agent expresses 4 immunostimulatory transgenes and works by crosslinking T cells to fibroblast activating-protein–positive cancer-associated fibroblasts, which activates the immune system. Additionally, CXCL9 and CXCL10 induce T-cell migration and interferon-α2 enhances T-cell activation and induces the killing of cancer cells by tumor antigen–specific T cells.

Already, NG-641 has shown encouraging preliminary safety and tolerability results in the ongoing phase 1a dose-escalation STAR trial (NCT04053283), which is a first-in-human study for the gene therapy.

When used in combination with nivolumab in the NEBULA study, the regimen is expected to result in complementary mechanisms of action.

Patients with metastatic or advanced epithelial cancers who have received prior anti–PD-1/PD-L1 therapy, have measurable disease, an ECOG performance status, adequate lung reserve, and adequate organ and bone marrow function are eligible to enroll in the trial. The included tumor types are urothelial carcinoma, squamous cell carcinoma of the head and neck, microsatellite instability–high or mismatch repair deficient cancers, non–small cell lung cancer, uterine or endometrial cancer, cervical cancer, esophageal cancer, gastric cancer, triple-negative breast cancer, cutaneous squamous cell carcinoma, hepatocellular carcinoma, and tumor mutational burden–high tumors.

Those with active infections, viral disease, autoimmune disease, acute kidney injury, renal impairment, or interstitial lung disease as well as patients with risk factors for bleeding or clotting events, bowel obstruction, or tumor flare are ineligible to participate in the trial.

A total of 30 patients are expected to be enrolled in the phase 1a portion of the trial, which consists of 5 escalating dose levels in a Bayesian Optimal Interval design. Phase 1b is the dose-expansion stage of the trial, which will consist of tumor-specific cohorts.

Dose level –1 is an intravenous infusion of NG-641 at 6 x 1011 virus particles (vp) given on days 1, 3, and 5; dose level 1 is 1 x 1012 vp of NG-641 on days 1, 3, and 5; dose level 2 is 1 x 1012 vp on day 1 followed by 3 x 1012 vp on days 3 and 5; dose level 3 is 1 x 1012 vp on day 1 followed by 6 x 1012 vp on days 3 and 5; and dose level 4 is 1 x 1012 vp on day 1 followed by 1 x 1013 vp on days 3 and 5. Across all dose levels, nivolumab will be administered at 480 mg on day 15 of the 4-week cycle.

The primary end point of the NEBULA trial is safety and tolerability as well as the recommended dose of the regimen. The secondary end point is preliminary antitumor activity. Additionally, pharmacokinetics, immunogenicity, and pharmacodynamics will be assessed using tumor tissue and blood samples.

Enrollment to the first cohort is currently ongoing in the United States at the UCLA Medical Center and in the United Kingdom at The Clatterbridge Cancer Centre, Oxford University Hospitals.


Lillie T, Parkes E, Ottensmeier C, et al. A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). Presented at: AACR Annual Meeting 2022; April 8-13, 2022; virtual. Abstract CT214.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Related Content